Anam Zubair, Bahisht Rizwan, Hooria Ajmal, Sahar Imran, Amsa Fatima
{"title":"口服维生素D3对肠易激综合征(IBS)患者生活质量的影响","authors":"Anam Zubair, Bahisht Rizwan, Hooria Ajmal, Sahar Imran, Amsa Fatima","doi":"10.54393/pjhs.v4i09.988","DOIUrl":null,"url":null,"abstract":"Irritable Bowel Syndrome (IBS) is the most prevailing complicated gastrointestinal disorder with an approximate 11.2% global prevalence, indicating a critical need for an improved understanding of the condition. Several studies suggested that adult IBS patients' symptoms and quality of life are markedly improved by vitamin D supplementation. Objective: To analyze the impact of oral Vitamin D3 supplementation on quality of life in patients with Intestinal Bowel Syndrome. Methods: A randomized control trial (RCT) was conducted for 9 months. Non-probability purposive sampling technique was used to allocate 24 participants aged between 25 to 35 years and BMI of 18–25. The participants were separated into two groups, G1 and G0. G1 received 50,000 IU of vitamin D weekly for 6 weeks. Results: Before the intervention, values of IBS-QOL for G1 were estimated as 1.8±0.71 while at the end of the intervention, there was a visible improvement in the values of IBS-QoL with the mean and SD determined as 2.4±0.51. The p-value for G1 was 0.002 which shows that there were significant improvements in the G1. Conclusions: The present study concluded that vitamin D supplementation can benefit patients with IBS by adding 5000 IU of vitamin D supplementation.","PeriodicalId":45690,"journal":{"name":"Pakistan Journal of Medical & Health Sciences","volume":"98 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Impact of Oral Vitamin D3 Supplementation on Quality of Life in Patients with Irritable Bowel Syndrome (IBS)\",\"authors\":\"Anam Zubair, Bahisht Rizwan, Hooria Ajmal, Sahar Imran, Amsa Fatima\",\"doi\":\"10.54393/pjhs.v4i09.988\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Irritable Bowel Syndrome (IBS) is the most prevailing complicated gastrointestinal disorder with an approximate 11.2% global prevalence, indicating a critical need for an improved understanding of the condition. Several studies suggested that adult IBS patients' symptoms and quality of life are markedly improved by vitamin D supplementation. Objective: To analyze the impact of oral Vitamin D3 supplementation on quality of life in patients with Intestinal Bowel Syndrome. Methods: A randomized control trial (RCT) was conducted for 9 months. Non-probability purposive sampling technique was used to allocate 24 participants aged between 25 to 35 years and BMI of 18–25. The participants were separated into two groups, G1 and G0. G1 received 50,000 IU of vitamin D weekly for 6 weeks. Results: Before the intervention, values of IBS-QOL for G1 were estimated as 1.8±0.71 while at the end of the intervention, there was a visible improvement in the values of IBS-QoL with the mean and SD determined as 2.4±0.51. The p-value for G1 was 0.002 which shows that there were significant improvements in the G1. Conclusions: The present study concluded that vitamin D supplementation can benefit patients with IBS by adding 5000 IU of vitamin D supplementation.\",\"PeriodicalId\":45690,\"journal\":{\"name\":\"Pakistan Journal of Medical & Health Sciences\",\"volume\":\"98 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-09-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pakistan Journal of Medical & Health Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.54393/pjhs.v4i09.988\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pakistan Journal of Medical & Health Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.54393/pjhs.v4i09.988","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Impact of Oral Vitamin D3 Supplementation on Quality of Life in Patients with Irritable Bowel Syndrome (IBS)
Irritable Bowel Syndrome (IBS) is the most prevailing complicated gastrointestinal disorder with an approximate 11.2% global prevalence, indicating a critical need for an improved understanding of the condition. Several studies suggested that adult IBS patients' symptoms and quality of life are markedly improved by vitamin D supplementation. Objective: To analyze the impact of oral Vitamin D3 supplementation on quality of life in patients with Intestinal Bowel Syndrome. Methods: A randomized control trial (RCT) was conducted for 9 months. Non-probability purposive sampling technique was used to allocate 24 participants aged between 25 to 35 years and BMI of 18–25. The participants were separated into two groups, G1 and G0. G1 received 50,000 IU of vitamin D weekly for 6 weeks. Results: Before the intervention, values of IBS-QOL for G1 were estimated as 1.8±0.71 while at the end of the intervention, there was a visible improvement in the values of IBS-QoL with the mean and SD determined as 2.4±0.51. The p-value for G1 was 0.002 which shows that there were significant improvements in the G1. Conclusions: The present study concluded that vitamin D supplementation can benefit patients with IBS by adding 5000 IU of vitamin D supplementation.
期刊介绍:
Pakistan Journal of Medical and Health Sciences is an international biomedical journal from Pakistan. We publish materials of interest to the practitioners and scientists in the broad field of medicine. Articles describing original qualitative, quantitative, human/animal clinical or laboratory studies are considered for publication.